<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03650491</url>
  </required_header>
  <id_info>
    <org_study_id>FOR46-002</org_study_id>
    <nct_id>NCT03650491</nct_id>
  </id_info>
  <brief_title>A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)</brief_title>
  <official_title>A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fortis Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fortis Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety and efficacy of FOR46 given every 21 days to patients with
      relapsed or refractory multiple myeloma.

      The name of the study drug involved in this study is: FOR46 for Injection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the safety, tolerability and antitumor activity of FOR46
      in patients with relapsed or refractory multiple myeloma. This study will be conducted in two
      parts:

      Dose escalation:

      This part will evaluate increasing doses of FOR46 to identify the maximum tolerated dose
      (MTD). The first patient enrolled on the study will receive the lowest dose of FOR46. Once
      this dose is shown to be safe, a second patient will be enrolled at the next higher dose.
      Patients will continue to be enrolled into either single or multiple patient groups receiving
      increasing doses until the MTD is reached.

      Dose expansion:

      This part of the study will further evaluate the safety, tolerability and antitumor activity
      of FOR46 at a dose shown to be safe in the dose escalation part of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Following completion of the dose escalation phase of the study and determination of a recommended phase 2 dose, patients will be enrolled into a dose expansion cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>Number of patients with treatment-related adverse events as assessed by NCI CTCAE v5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of dose-limiting toxicities</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>The severity and incidence of dose-limiting toxicities related to escalating dose levels of FOR46</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease response</measure>
    <time_frame>6 months</time_frame>
    <description>Overall response rate of FOR46, defined as all responses greater than or equal to a partial response, complete response, stringent complete response, or minimal residual disease negativity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize FOR46 plasma concentration</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>FOR46 maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the FOR46 area under the curve</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>FOR46 area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize FOR46 elimination</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>FOR46 elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug Antibodies</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>Change from baseline in serum levels of antidrug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From first dose through 6 months following last dose</time_frame>
    <description>Assessed by IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From first dose through 6 months following last dose</time_frame>
    <description>Assessed by IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>From first dose through 6 months following last dose</time_frame>
    <description>Assessed by IMWG criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Multiple Myeloma in Relapse</condition>
  <condition>Multiple Myeloma With Failed Remission</condition>
  <arm_group>
    <arm_group_label>Experimental: FOR46 (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: FOR46 (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOR46</intervention_name>
    <description>FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46</description>
    <arm_group_label>Experimental: FOR46 (Dose Escalation)</arm_group_label>
    <arm_group_label>Experimental: FOR46 (Dose Expansion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 years of age

          -  Measurable MM that is relapsed or refractory to established therapies with known
             clinical benefit in RRMM or intolerant of those established MM therapies. Prior lines
             of therapy must include a proteasome inhibitor (PI), an immunomodulatory imide drug
             (IMiD) and a CD38-directed therapy in any order of combination.

          -  ECOG performance status of 0 or 1

          -  Adequate hematologic, renal and hepatic function

          -  Females of child-bearing potential must have a negative serum pregnancy test and use a
             medically acceptable form of contraception

          -  Male patients with with female partners of childbearing potential must agree to use 2
             effective methods of contraception

          -  Patients must provide signed informed consent

        Exclusion Criteria:

          -  Persistent clinically significant toxicities from previous anticancer therapy

          -  NCI CTCAE Grade ≥ 2 peripheral neuropathy from any etiology

          -  Has received treatment with a stem cell transplant within 12 weeks before
             administration of patient's first dose of FOR46

          -  Has had radiation or systemic anticancer therapy within 14 days before first dose of
             FOR46

          -  Has received treatment with an investigational drug within 28 days before first dose
             of FOR46

          -  Clinically significant cardiovascular disease

          -  Uncontrolled, clinically significant pulmonary disease

          -  Uncontrolled intercurrent illness

          -  Requires medications that are strong inhibitors or strong inducers of CYP3A4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Dorr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fortis Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Dorr, MD</last_name>
    <phone>858-504-1453</phone>
    <email>adorr414@me.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rocio Navarro</last_name>
    <phone>301-762-6100</phone>
    <phone_ext>162</phone_ext>
    <email>RNavarro@rrdintl.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phu Lam</last_name>
      <phone>415-353-8337</phone>
      <email>Phu.Lam@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Comerford</last_name>
      <phone>415-514-6674</phone>
      <email>Kathleen.Comerford@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sandy Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Schatz</last_name>
      <phone>720-848-0628</phone>
      <email>derek.schatz@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Noelle Mahleres</last_name>
      <phone>720-848-2409</phone>
      <email>noelle.mahleres@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tomer Mark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Spivey</last_name>
      <phone>404-712-1739</phone>
      <email>stephen.spivey@emoryhealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Shondolyn Richburg</last_name>
      <email>shondolyn.richburg@emoryhealthcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Kaufman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Stevens</last_name>
      <phone>443-287-0180</phone>
      <email>msteve35@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Phillip Imus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Pregja</last_name>
      <phone>313-576-8673</phone>
      <email>pregjas@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Zonder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis-Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Allen</last_name>
      <phone>314-747-3094</phone>
      <email>klallen@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Mark A Schroeder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mt. Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Zarychta</last_name>
      <phone>212-241-2495</phone>
      <email>katarzyna.zarychta@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Ajai Chari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

